Shares dropped 14.9% following the quarter as investors reacted negatively to a revised full-year revenue outlook amid ongoing coding and reimbursement challenges, compounded by headwinds from the new WISER prior authorization program.

• Revenue growth and adjusted operating income improved versus prior year, but underlying operational challenges persist.
• Significant coding and reimbursement uncertainties remain, particularly for the Inspire V system, with only partial short-term solutions in place.
• Medicare’s new C-code for Inspire V provides some clarity, but broader commercial payer coding remains inconsistent, requiring manual reviews and prior authorizations.
• The WISER program introduced prior authorization delays in six states, adversely impacting first-quarter revenue and creating ongoing headwinds.
• Management is increasing customer support and education to improve prior authorization success and expects coding and reimbursement trends to stabilize later in the year.